Every 424B that AETHLON MEDICAL INC (AEMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AEMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEMD filings page.
Aethlon Medical, Inc. is offering 263,000 shares of common stock, pre-funded warrants to purchase 5,370,009 shares and common warrants to purchase 5,633,009 shares at a combined public offering price of $0.71 per share (or pre-funded warrant) and accompanying warrant. The offering also registers the 11,228,338 shares issuable upon exercise of the warrants, pre-funded warrants and placement agent warrants. The offering is structured on a best-efforts basis with no minimum and includes placement agent warrants equal to 4% of shares issued. Common warrants have a $0.71 exercise price and will be exercisable upon stockholder approval or earlier if specified Pricing Conditions are met. Proceeds examples in the prospectus show a maximum public offering amount of $4,000,000 and estimated proceeds before expenses of $3,740,000. The company discloses material risks including substantial doubt about its ability to continue as a going concern and Nasdaq continued-listing risks.
AEMD amends its ATM prospectus supplement to update the remaining capacity under its Form S-3 at-the-market program. The amendment states an available aggregate offering price of $542,716 to be sold from time to time through H.C. Wainwright & Co. under the sales agreement. The company reports a public float of $7,176,521 based on 2,337,629 shares held by non-affiliates at a highest closing price of $3.07 per share as of May 27, 2026, and notes prior ATM sales of $1,849,457 during the prior 12 months. Sales are governed by General Instruction I.B.6 of Form S-3 and may be made as at-the-market offerings on Nasdaq or through other permitted methods under the sales agreement.
Aethlon Medical, Inc. has an effective resale registration covering up to 2,031,024 shares of common stock, issuable from previously issued warrants and pre-funded warrants held by selling securityholders. This prospectus supplement and related agreements remove the prior requirement that the pre-funded warrants receive stockholder approval before exercise, so those pre-funded warrants are now immediately exercisable, subject to beneficial ownership limits and existing terms. The underlying warrant agreements and securities purchase agreement are otherwise unchanged, and the company’s common stock continues to trade on Nasdaq under the symbol AEMD.
Aethlon Medical, Inc. has filed a prospectus to register up to 2,031,024 shares of common stock for resale by existing securityholders. These shares are issuable from previously sold Common Warrants, Pre-Funded Warrants, Inducement Warrants and Placement Agent Warrants tied to a December 2025 private financing and warrant inducement transaction. The company will not receive proceeds from the resale itself, but could receive cash if holders exercise the warrants, which mostly have exercise prices of $4.03 or $5.04 per share versus a recent Nasdaq price of $2.75. All warrants become exercisable only after required stockholder approval under Nasdaq rules, and the common warrants will have no value if that approval is not obtained. Aethlon is a smaller reporting company developing the Hemopurifier, a clinical-stage blood-filtration device targeting cancer-related extracellular vesicles and life‑threatening enveloped viruses, with early oncology trials underway in Australia and a similar study planned in India.